Liquid biopsy uses circulating tumor DNA (ctDNA) to detect minute quantities of tumor DNA in the blood. In a recent study presented at the ASCO 2022 meeting, researchers used ct DNA to determine which patients with stage 2 Colon cancer would benefit from chemotherapy. The study, called the Dynamic trial, looked at circulating tumor DNA before and after surgery. Patients were assigned to the chemotherapy or no-chemotherapy group based on their ctDNA results. The authors found that patients who had a complete response to surgery (no ctDNA detected) did not benefit from chemotherapy. In contrast, those with residual disease (ctDNA present) significantly benefited from chemotherapy. These findings suggest that liquid biopsy can be used to guide decision-making in colon cancer.
The use of circulating tumor DNA is a relatively new concept, and more studies are needed to confirm these findings. However, this study provides proof of concept that liquid biopsy can be used to guide treatment decisions in colon cancer. This is an important step forward in personalized medicine.
If you have been diagnosed with Colon cancer, talk to your doctor about whether liquid biopsy is right for you.
https://meetings.asco.org/abstracts-presentations/209173
What do you think about these findings? Share your thoughts in the comments below.
Recent Comments